Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1977 3
1978 1
1994 1
1995 1
1996 1
1998 1
2003 2
2004 1
2007 2
2008 4
2009 2
2010 3
2011 4
2012 6
2013 2
2015 3
2016 4
2017 6
2018 3
2019 8
2020 7
2021 10
2022 9
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).
Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, Uchi H, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, Yamazaki N. Kamimura A, et al. Among authors: uehara j. J Dermatol. 2022 Sep;49(9):837-844. doi: 10.1111/1346-8138.16422. Epub 2022 May 5. J Dermatol. 2022. PMID: 35510662
Sweat-gland carcinoma with neuroendocrine differentiation (SCAND): a clinicopathologic study of 13 cases with genetic analysis.
Goto K, Kukita Y, Honma K, Ohike N, Komori T, Ishida Y, Ishikawa M, Nakatsuka T, Fumita S, Nakagawa K, Okabayashi A, Iwahashi Y, Tanino T, Kikuchi K, Kawahara Y, Hishima T, Uehara J, Oishi T, Isei T. Goto K, et al. Among authors: uehara j. Mod Pathol. 2022 Jan;35(1):33-43. doi: 10.1038/s41379-021-00921-8. Epub 2021 Sep 12. Mod Pathol. 2022. PMID: 34518631 Free article.
Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study.
Kato J, Namikawa K, Uehara J, Nomura M, Nakamura Y, Uhara H, Uchi H, Yoshikawa S, Kiniwa Y, Nakamura Y, Miyagawa T, Matsushita S, Takenouchi T, Hatta N, Ohno F, Maeda T, Fukushima S, Yamazaki N. Kato J, et al. Among authors: uehara j. Br J Dermatol. 2022 Oct;187(4):594-596. doi: 10.1111/bjd.21276. Epub 2022 Jun 7. Br J Dermatol. 2022. PMID: 35347707 No abstract available.
75 results